Logo
x

Search

Subscribe Now

zai lab

Zai Lab and argenx Report the NMPA’s Approval of Efgartigimod Alfa SC Injection to Treat Generalized Myasthenia Gravis

Zai Lab and argenx Report the NMPA’s Approval of Efgartigimod Alfa SC Injection to Treat Generalized Myasthenia Gravis

  • July 16, 2024
Zai Lab and Innoviva Specialty Therapeutics Reports the NMPA’s Approval of Xacduro (sulbactam-durlobactam) for Hospital-Acquired and Ventilator-Associated Pneumonia

Zai Lab and Innoviva Specialty Therapeutics Reports the NMPA’s Approval of Xacduro (sulbactam-durlobactam) for Hospital-Acquired a...

  • May 20, 2024
Zai Lab’s Augtyro Receives the NMPA’s Approval to Treat Non-Small-Cell Lung Cancer (NSCLC)

Zai Lab’s Augtyro Receives the NMPA’s Approval to Treat Non-Small-Cell Lung Cancer (NSCLC)

  • May 13, 2024
Zai Lab and Novocure Report P-III Trial (LUNAR) Results of Tumor Treating Fields Therapy for Metastatic Non-Small Cell Lung Cancer

Zai Lab and Novocure Report P-III Trial (LUNAR) Results of Tumor Treating Fields Therapy for Metastatic Non-Small Cell Lung Cancer

  • June 7, 2023
Zai Lab Partner argenx Report Results of Vyvgart (efgartigimod alfa-fcab) P-III (ADVANCE) Trial for Primary Immune Thrombocytopenia

Zai Lab Partner argenx Report Results of Vyvgart (efgartigimod alfa-fcab) P-III (ADVANCE) Trial for Primary Immune Thrombocytopeni...

  • May 6, 2022
PharmaShots Interview: Zai Lab’s Jonathan Wang Shares Insights on KarXT (xanomeline-trospium) for the Treatment of Schizophrenia And Psychosis

PharmaShots Interview: Zai Lab’s Jonathan Wang Shares Insights on KarXT (xanomeline-trospium) for the Treatment of Schizophrenia A...

  • February 28, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.